Christiaan De Wilde succeeds Frank Morich as Innogenetics' CEO
Christiaan De Wilde will start his new assignment effective October 15th, 2007. He brings to this position a wealth of senior executive experience in financial controlling and business strategy. Prior to joining Innogenetics in 2006, Christiaan built a 17-year career at Johnson & Johnson and served at different senior executive positions, including as Finance & Logistics Director Benelux of Johnson & Johnson Medical from June 2000 until May 2005. He was appointed Member of the Board of Directors at Janssen-Cilag Belgium NV in May 2005.
The Board has begun a search for a permanent replacement CFO and expects to complete the search by year end. Christiaan De Wilde will act in a joint capacity as CEO and CFO during the interim period.
Organizations
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.